Frontier Biotechnologies Inc.'s (SHSE:688221) Biggest Owners Are Individual Investors Who Got Richer After Stock Soared 18% Last Week
Frontier Biotechnologies Inc.'s (SHSE:688221) Biggest Owners Are Individual Investors Who Got Richer After Stock Soared 18% Last Week
Key Insights
主要见解
- Frontier Biotechnologies' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public
- 50% of the business is held by the top 16 shareholders
- Insider ownership in Frontier Biotechnologies is 16%
- Frontier Biotechnologies的重要个人投资者所有权表明,关键决策受到来自更大公众的股东的影响。
- 前16名股东持有该业务50%的股份。
- Frontier Biotechnologies的内部持股比例为16%。
Every investor in Frontier Biotechnologies Inc. (SHSE:688221) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual investors with 48% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
Frontier Biotechnologies Inc.(SHSE:688221)的每个投资者都应该了解最强大的股东团体。而拥有最大股份的是持有48%股权的个人投资者团体,即如果股票上涨,该团体将获益最多,如果出现下跌,则将失去最多。
As a result, individual investors were the biggest beneficiaries of last week's 18% gain.
因此,个人投资者是上周18%收益的最大受益者。
Let's take a closer look to see what the different types of shareholders can tell us about Frontier Biotechnologies.
让我们仔细看看不同类型的股东可以告诉我们什么关于Frontier Biotechnologies。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240625/0-000f00c6b5c7740f6f8e0d13afb6b41e-0-c0e967d28dc369d015963c7941fedf7b.png/big)
What Does The Institutional Ownership Tell Us About Frontier Biotechnologies?
机构持股告诉我们什么关于Frontier Biotechnologies?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构衡量其业绩的标准是一个近似于当地市场的指数。因此,他们通常更加关注包括在主要指数中的公司。
We can see that Frontier Biotechnologies does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Frontier Biotechnologies' earnings history below. Of course, the future is what really matters.
我们注意到,Frontier Biotechnologies确实拥有机构投资者,并且他们持有公司的大部分股票。这意味着为这些机构工作的分析师已经看过该股票,并且他们喜欢它。但是就像其他人一样,他们可能是错误的。如果多个机构在同一时间改变其对一只股票的看法,您可能会看到股价迅速下跌。因此,值得看一下下面的Frontier Biotechnologies收入历史记录。当然,未来才是真正重要的。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240625/0-000f00c6b5c7740f6f8e0d13afb6b41e-1-18bdbb5a17d598673f9b00770b827e43.png/big)
We note that hedge funds don't have a meaningful investment in Frontier Biotechnologies. Our data shows that Baobab Pharmaceuticals Limited is the largest shareholder with 19% of shares outstanding. With 5.8% and 5.6% of the shares outstanding respectively, Rongjian Lu and Changjin Wang are the second and third largest shareholders. Interestingly, the bottom two of the top three shareholders also hold the title of Chief Technology Officer and Member of the Board of Directors, respectively, suggesting that these insiders have a personal stake in the company.
我们注意到,对于Frontier Biotechnologies,对冲基金没有实质性投资。我们的数据显示,Baobab Pharmaceuticals Limited是最大的股东,拥有19%的流通股。Rongjian Lu和Changjin Wang分别拥有流通股的5.8%和5.6%,是第二和第三大股东。有趣的是,前三名股东中的后两名还拥有首席技术官和董事会成员的头衔,这表明这些内部人士在公司中有个人利益。
A closer look at our ownership figures suggests that the top 16 shareholders have a combined ownership of 50% implying that no single shareholder has a majority.
我们的所有权数字显示,前16名股东的所有权总计占50%,这意味着没有单一股东占有多数。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.
尽管我们需要研究一个公司的机构所有权数据是有道理的,但也需要研究分析师的情绪来了解市场趋势。我们目前没有发现任何关于该股票的分析师报道,所以该公司可能不受广泛持有。
Insider Ownership Of Frontier Biotechnologies
Frontier Biotechnologies的内部持股
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间有所不同。我们的数据反映了个人内部人员,至少捕捉到董事会成员的记录。公司管理人员向董事会报告,后者应该代表股东的利益。值得注意的是,有时高级管理人员自己也在董事会中。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。
Our information suggests that insiders maintain a significant holding in Frontier Biotechnologies Inc.. Insiders own CN¥397m worth of shares in the CN¥2.5b company. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.
我们的信息表明,内部人士在Frontier Biotechnologies Inc.中持有大量股份。内部人士拥有价值3.97亿人民币的股票,占2.5亿人民币公司的股份。这可能表明创始人仍然拥有很多股份。你可以点击这里查看他们是否一直在购买或出售。
General Public Ownership
一般大众所有权
The general public-- including retail investors -- own 48% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
公众,包括散户投资者,在该公司中拥有48%的股权,因此不容忽视。虽然该团体不能确定决策,但它肯定会对公司的运营产生实际影响。
Private Company Ownership
私有公司的所有权
It seems that Private Companies own 29%, of the Frontier Biotechnologies stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
似乎私有公司拥有Frontier Biotechnologies股票的29%。仅从这个事实很难得出任何结论,因此值得进一步了解谁拥有这些私有公司。有时,内部人士或其他相关方通过单独的私有公司拥有公共公司的股权。
Next Steps:
下一步:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 2 warning signs we've spotted with Frontier Biotechnologies (including 1 which doesn't sit too well with us) .
我觉得查看公司所有者非常有趣。但是为了真正获得洞察力,我们需要考虑其他信息。为此,您应该了解我们发现的2个警告信号(包括一个我们不太喜欢的信号)。
Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.
当然,这也可能不是最好的股票交易。因此,您可能想看看我们免费的潜力股票收藏,这些股票具有有利的财务状况。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。